Delivering on the promise of genetic medicine to detect and cure disease.
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.
Our leadership team is comprised of cutting edge scientific research and business achievement.
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in-vivo editing.
Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is a Malaria No More “10 to END” innovator.
As co-founder and Chief Technology Officer of Mammoth Biosciences, Janice leads the Applied program by implementing CRISPR-based DETECTR technology towards disease detection and other areas. Janice received her Ph.D. in Molecular and Cell Biology in Jennifer Doudna's lab at UC Berkeley. She has authored multiple publications and patents related to CRISPR mechanism and technologies, and co-invented the programmable CRISPR-based detection technology called DETECTR. Janice was selected as a 2019 Forbes 30 Under 30 in Healthcare, and delivered a TEDx talk in 2018 on the potential for CRISPR to democratize diagnostics.
As co-founder and Chief Science Officer of Mammoth Biosciences, Lucas drives the development of next-generation CRISPR products and leads the scientific research program for new discoveries. He focuses on harnessing microbial diversity to build novel CRISPR applications for DNA detection and genome editing. At UC Berkeley, Lucas worked in Jennifer Doudna’s lab and authored multiple scientific papers, the latest of which features his discovery of the newest Cas system to date, Cas14, in Science. He received a BS in Chemistry from Washington University in St. Louis, where he researched bacterial photosynthesis.
Co-founder, Chair of Scientific Advisory Board
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by discovering a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria, known as CRISPR. Doudna is an Investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. She is also a Foreign Member of the Royal Society and has received many other honors including, the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award and the Japan Prize.
Gary joined Mammoth from Sangamo, where he was EVP, General Counsel and Chief Compliance Officer. Gary has also been General Counsel at several Bay Area biotechnology companies including Amyris, Achaogen and Counsyl. In addition to serving in operational roles leading business development, human resources, facilities, IT, and regulatory, Gary has deep expertise in licensing and intellectual property. He was at Genentech for over 11 years, ultimately leading the intellectual property, litigation, and corporate records functions as VP of Intellectual Property. Gary earned his J.D. from Columbia Law School and his B.S. (Biological Sciences) and B.A. (English) from Stanford University. Gary has lectured as an Adjunct Professor at the University of San Francisco School of Law since 2006.
Chief Financial Officer and Chief Operating Officer
Elaine joined Mammoth from Halozyme Therapeutics, where she was SVP and Chief Financial Officer of a profitable, commercial-stage biotechnology company. Prior to Halozyme, she served as Chief Financial Officer and Chief Strategy Officer at SutroVax (now Vaxcyte), a developer of next-generation pneumococcal conjugate vaccines. Elaine brings with her 25 years of experience in the life sciences industry, including building and growing both private and public companies. While at SutroVax, she provided strategic, operational and financial leadership for a rapidly growing organization, including establishing innovative supply partnership agreements. Previously, Elaine served as Managing Director and Head of West Coast Healthcare at Evercore Partners and Managing Director at Merrill Lynch. Over her investment banking career, she led and played key roles in a broad range of pharmaceutical, biotechnology and medical device M&A and financing transactions valued in excess of $50 billion. She currently serves on the Board of Directors of Dynavax Technologies and previously served on the Board of Directors of Cirius Therapeutics. Elaine received her BA from Wellesley College and MBA from Harvard Business School.
Chief Agility Officer
Ted is the Chief Agility Officer at Mammoth Biosciences after two and half years of building the infrastructure as COO and is focused on implementing agile processes, systems and structure to support the internal technical teams. Previously, as COO at Synthego Corporation, he built the product management, commercial, and manufacturing operations functions as the company progressed from Series A to Series D funding. Ted served as Vice President-General Manager for the Protein Function Division at Bio-Rad Laboratories with global P&L responsibilities spanning multiple proteomics and molecular biology businesses.
Senior Vice President of Research and Development - Diagnostics
Senior VP of R&D - Diagnostics, Jesus Ching, Ph.D. brings 30 years of experience building innovative technologies in the in vitro diagnostics space to lead the development of Mammoth’s next-generation CRISPR tools. Jesus kicked off his career directing and launching diagnostics products at Cepheid. Afterward, he co-founded and sold GenturaDx to Luminex Corporation, and has since held various C-Suite positions at organizations ranging from Click Diagnostics to Coyote Biosciences, where he set technical and IP strategy. Jesus received his Ph.D. in Chemistry from Baylor University.
Senior Vice President of Product Development - Diagnostics
As Senior VP of Product Development, Tim Patno leverages 30 years of extensive regulatory and product development experience to oversee the manufacturing of Mammoth Biosciences’ diagnostics products. Prior to Mammoth, Tim spent nine years at Baxter Healthcare, then went on to develop and launch Nanosphere’s Verigene system. Most recently, Tim built and launched multiple products for large and small companies’ integrated molecular diagnostic assays. Tim has his Masters in Electrical Engineering from the University of Southern California.
Adriana Dantas Lemberg
Vice President of Product Management - Diagnostics
VP Product Management Diagnostics, Adriana Dantas Lemberg joined us from Roche, where she held several positions, including Global VP of Point of Care, based in Switzerland and Global VP of Non Invasive Prenatal Testing at Roche Molecular Systems, based in the US.
With over 25 years of experience in the Medical Device and IVD Diagnostics Industry, having led complex cross functional teams from early research stage to successful commercial execution, Adriana brings strong leadership and deep expertise in strategic marketing and product launches in various markets segments, including at the POC and retail, in several geographies across the globe. She is a Biochemist and PharmD from the University of Sao Paulo and a MBA from Fundacao Getulio Vargas/Sao Paulo and Cranfield University/UK.
Head of Business Development
Vikram Joshi is Mammoth’s Head of Business Development. A startup veteran and corporate leader within the in vitro diagnostics industry, he has over 15 years of experience in business development, product management, and operations. Vikram brings a successful track record of partnering, capital raising, and defining corporate strategy for healthcare organizations. Vikram earned degrees in Materials Science and Engineering from Cornell University and Stanford University. He also holds an MBA from the Wharton School of the University of Pennsylvania with a focus on entrepreneurship and healthcare management.
Vice President of Genome Engineering
VP of Genome Engineering, Dimitrios Zisoulis, Ph.D., brings gene therapy development experience to lead the preclinical R&D efforts for Mammoth’s next-generation CRISPR gene-editing therapeutics. Dimitrios earned his doctoral degree from Northwestern University, studying gene regulation in the immune system, and completed his postdoctoral training at UCSD on microRNA-mediated gene regulation. His gene therapy background includes microRNAs and oligonucleotides (RegulusTx), developing mRNA therapeutics (TranscripTx, now RecodeTx), and CRISPR-based and protein engineered RNA-targeting systems (Locanabio), as well as viral and non-viral gene delivery platforms.
VP of Intellectual Property and Associate General Counsel
VP of IP, Rachel Herder, Ph.D. leads Mammoth Biosciences’ robust IP strategy. She joins the team with eight years of experience as a patent attorney representing startups, both at a leading intellectual property law firm and as the Director of the Intellectual Property Clinic at Penn State Law. Rachel has focused her career on representing clients in the genome editing and gene diagnostic spaces and has advised startup life science clients on various aspects of intellectual property law, including patent prosecution, litigation, and global patent strategy. Rachel received both her J.D. and Ph.D. in Molecular Cellular Developmental Biology & Genetics from Michael B. O'Connor's lab at the University of Minnesota.
VP of Finance
VP of Finance, Susan Wong brings over 25 years of corporate financial management and accounting experience to her position, over half of which has been in the venture-backed companies in the life sciences industry. Prior to joining Mammoth Biosciences, she was VP of Finance at Neurona Therapeutics where she led the finance and accounting functions. In her span of career, Susan held leadership positions serving in the capacity of CFO/Controller consultants at Osprey Pharmaceuticals, Cerimon Pharmaceuticals, Epiphany Biosciences and Cellerant Therapeutics. She was an educator and had taught finance and accounting courses at UC Berkeley extension and Menlo College. Susan received a BS degree from University of Hawaii, a Master of Business Administration from Santa Clara University and Master of Accountancy from Golden Gate University.